carmustine has been researched along with Leukopenia in 26 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 9.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 9.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 7.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| "Sixty-five patients with multiple myeloma resistant to melphalan were randomized to receive cyclophosphamide, doxorubicin (Adriamycin), and prednisone (CAP) (30 patients) or carmustine (BCNU), doxorubicin, and prednisone (BAP) (35 patients)." | 5.05 | Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone. ( Brunner, K; Henderson, ES; Henry, PH; Holland, JF; Kyle, RA; McIntyre, OR; Nawabi, IU; Pajak, TF, 1982) |
| "A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0." | 5.05 | Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. ( Brunner, K; Cooper, MR; Cornwell, GG; Cuttner, J; Glowienka, LP; Haurani, FI; Henderson, E; Kochwa, S; Kyle, RA; McIntyre, OR; Pajak, TF; Rafla, S; Silver, RT, 1982) |
| "Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) against a regimen employing oral melphalan (MP)." | 5.04 | Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. ( Coleman, M; Cooper, MR; Cuttner, J; Harley, JB; Kochwa, S; McIntyre, OR; Pajak, TF, 1979) |
| "Twenty-three patients with metastatic melanoma were treated with combination therapy consisting of dacarbazine (220 mg/m2) and cisplatin (25 mg/m2) iv daily for 3 days every 3 weeks, carmustine (150 mg/m2) iv every 6 weeks, and tamoxifen (10 mg) orally twice daily." | 3.67 | Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. ( Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF, 1987) |
| "From January 1975 to May 1981, 25 consecutive patients with multiple myeloma (MM) were entered in a prospective study and treated with the M-2 protocol (melphalan, prednisone, cyclophosphamide, vincristine, and carmustine [BCNU])." | 3.66 | Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). ( Carbone, A; Crivellari, D; Galligioni, E; Grigoletto, E; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1982) |
| " The dosage of CCNU was 100 mg/m2 p." | 2.65 | The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. ( Brunner, K; Cuttner, J; Falkson, G; Hansen, HH; Holland, JF; Nissen, NI; Pajak, TF; Selawry, OS; Spurr, CL, 1981) |
| "It is an effective drug in the treatment of malignant melanoma with better response rates in women than in men." | 2.64 | Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group. ( Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (84.62) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crider, AM | 1 |
| Lamey, R | 1 |
| Floss, HG | 1 |
| Cassady, JM | 1 |
| Bradner, WJ | 1 |
| Hua, XM | 1 |
| Ren, XW | 1 |
| Liu, FL | 1 |
| Liu, Y | 1 |
| Zhang, CJ | 1 |
| Li, ZJ | 1 |
| Xu, L | 1 |
| Liu, JY | 1 |
| Liu, YG | 1 |
| Stewart, DJ | 1 |
| Benoit, B | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Dennery, J | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Grahovac, Z | 1 |
| Belanger, G | 1 |
| Maroun, JA | 1 |
| Bonnet, JD | 1 |
| Alexanian, R | 1 |
| Salmon, SE | 1 |
| Haut, A | 1 |
| Dixon, DO | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 1 |
| Bernardo, G | 1 |
| Knerich, R | 1 |
| Butti, G | 1 |
| Cuzzoni, Q | 1 |
| Oken, MM | 1 |
| Costello, WG | 1 |
| Johnson, GJ | 1 |
| Lenhard, RE | 1 |
| Ezdinli, EZ | 2 |
| Orlow, E | 1 |
| Barnes, JM | 1 |
| Berard, CW | 1 |
| Glick, JH | 2 |
| Tirelli, U | 1 |
| Crivellari, D | 1 |
| Carbone, A | 1 |
| Veronesi, A | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Hansen, HH | 1 |
| Selawry, OS | 1 |
| Pajak, TF | 4 |
| Spurr, CL | 1 |
| Falkson, G | 1 |
| Brunner, K | 3 |
| Cuttner, J | 3 |
| Nissen, NI | 1 |
| Holland, JF | 2 |
| Kyle, RA | 2 |
| Henderson, ES | 1 |
| Nawabi, IU | 1 |
| Henry, PH | 1 |
| McIntyre, OR | 3 |
| Cornwell, GG | 1 |
| Kochwa, S | 2 |
| Glowienka, LP | 1 |
| Rafla, S | 1 |
| Silver, RT | 1 |
| Cooper, MR | 2 |
| Henderson, E | 1 |
| Haurani, FI | 1 |
| Brandes, AA | 1 |
| Scelzi, E | 1 |
| Zampieri, P | 1 |
| Rigon, A | 1 |
| Rotilio, A | 1 |
| Amista, P | 1 |
| Berti, F | 1 |
| Fiorentino, MV | 1 |
| Kleinberg, L | 1 |
| Grossman, SA | 1 |
| Piantadosi, S | 1 |
| Zeltzman, M | 1 |
| Wharam, M | 1 |
| Harley, JB | 1 |
| Coleman, M | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, W | 1 |
| Hill, G | 1 |
| Krementz, E | 1 |
| Costanzi, JJ | 1 |
| Case, DC | 1 |
| Ervin, TJ | 1 |
| Boyd, MA | 1 |
| Redfield, DL | 1 |
| Mbidde, EK | 1 |
| Selby, PJ | 1 |
| Perren, TJ | 1 |
| Dearnaley, DP | 1 |
| Whitton, A | 1 |
| Ashley, S | 1 |
| Workman, P | 1 |
| Bloom, HJ | 1 |
| McElwain, TJ | 1 |
| McClay, EF | 1 |
| Mastrangelo, MJ | 1 |
| Bellet, RE | 1 |
| Berd, D | 1 |
| Anderson, JR | 1 |
| Melvin, F | 1 |
| Davis, TE | 1 |
| O'Connell, MJ | 1 |
| Tribalto, M | 1 |
| Amadori, S | 1 |
| Cantonetti, M | 1 |
| Franchi, A | 1 |
| Papa, G | 1 |
| Pileri, A | 1 |
| Boccadoro, M | 1 |
| Dammacco, F | 1 |
| Vacca, A | 1 |
| Centurioni, R | 1 |
| Desser, RK | 1 |
| Ultmann, JE | 1 |
| Fewer, D | 1 |
| Wilson, CB | 1 |
| Boldrey, EB | 1 |
| Enot, KJ | 1 |
| Powell, MR | 1 |
| Tormey, DC | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| Cohen, SM | 1 |
| Greenspan, EM | 1 |
| Weiner, MJ | 1 |
| Kabakow, B | 1 |
| Gottlieb, JA | 1 |
| Rivkin, SE | 1 |
| Spigel, SC | 1 |
| Hoogstraten, B | 1 |
| O'Bryan, RM | 1 |
| Delaney, FC | 1 |
| Singhakowinta, A | 1 |
| Kovach, JS | 1 |
| Moertel, CG | 1 |
| Schutt, AJ | 1 |
| Hahn, RG | 1 |
| Reitemeier, RJ | 1 |
1 review available for carmustine and Leukopenia
| Article | Year |
|---|---|
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singly.
Topics: Adrenal Cortex Hormones; Alopecia; Antineoplastic Agents; Bleomycin; Blood Platelet Disorders; Carmu | 1973 |
13 trials available for carmustine and Leukopenia
| Article | Year |
|---|---|
[Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-C | 2004 |
The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study.
Topics: Adult; Carmustine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration S | 1981 |
Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Topics: Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Therap | 1982 |
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Topics: Antineoplastic Agents; Carmustine; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1982 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
Topics: Alkylating Agents; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Humans; Leukopenia; Melp | 1979 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Femal | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Co | 1976 |
Waldenström's macroglobulinemia: long-term results with the M-2 protocol.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Dru | 1991 |
Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Female; Follow-Up Stud | 1985 |
Treatment of multiple myeloma: a randomized study of three different regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Carmustine; Clinical Trials as | 1985 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
Triple combination chemotherapy of disseminated melanoma.
Topics: Aged; Alkylating Agents; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Drug Combinati | 1972 |
12 other studies available for carmustine and Leukopenia
| Article | Year |
|---|---|
Synthesis of nitrosourea derivatives of pyridine and piperidine as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Leukemia, Experimental; Leukopenia; Mice; Neoplasms, Experimental; N | 1980 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Doxorubicin; Drug | 1984 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
The influence of histologic subtype on toxicity and response to chemotherapy in non-hodgkin's lymphoma. An Eastern Cooperative Oncology Group Study utilizing the BCVP regimen.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; | 1983 |
Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycl | 1982 |
The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Ci | 1999 |
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Ther | 1988 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Fem | 1987 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Carmustine; Cyclohexanes; Doxorubicin; Female; Humans | 1974 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |